Pangtao

Our lab's research is focused on the role of neuroinflammation mediated by microglia and other immune cells in ischemic stroke and elucidation of detailed molecular mechanisms, with the aim of discovery of potential drug targets and drug candidates against stroke. Currently, our lab has published over 40 papers including Cell Rep Med、Brain Behav Immun、Pharmacol Res、Angew Chem Int Ed Engl、Acta Pharm Sin B, etc. We have applied 26 domestic and international patents and 18 patents were authorized. We have received more than 10 grants from our province government and the National Natural Science Foundation of China. 

Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke - Published in Cell Reports Medicine, 2024.

A novel SIRT6 activator ameliorates neuroinflammation and ischemic brain injury via EZH2/Foxc1 axis - Published in Acta Pharmaceutica Sinica B., 2021.

Synthesis and target identification of benzoxepane derivatives as potential anti-neuroinflammatory agents for ischemic stroke - Published in Angewandte Chemie International Edition, 2020.

Liposomal 9-aminoacridine for treatment of ischemic stroke: from drug discovery to drug delivery - Published in Nano Letters, 2020

Study the role of neuroinflammation in ischemic stroke to discover and validate potential drug target and therapeutics.

“The CNPHARS-SERVIER Young Investigator Awards in Pharmacology”, Chinese Pharmacological Society (CNPHARS) and Servier (2018)

“The Youth Pharmacologist Award”, Chinese Pharmacological Society (2017)

“Outstanding Youth Award of Jiangsu Medical Science and Technology”, Jiangsu Association for Drug Research and Development (2017)

“Tony B. Travel Award”, Society for Laboratory Automation and Screening (USA) (2015, 2016)

“President’s Excellent Award”, Chinese Academy of Sciences (2007)